Kabra Drugs Limited submitted a formal undertaking to BSE Limited regarding the non-applicability of Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended 31st March 2026.
The disclosure specifically addresses the requirements under Regulation 32, which mandates listed entities to submit statements indicating: (a) deviations in the use of proceeds from objects stated in offer documents, and (b) category-wise variations between projected and actual utilization of funds for public issues, rights issues, or preferential issues.
The company certified that these compliance requirements are not applicable as Kabra Drugs Limited did not issue any shares through public issue, rights issue, preferential issue, or similar methods during the quarter ended 31st March 2026.
The undertaking was digitally signed by Mr. Nanjappan Aravind, Managing Director of Kabra Drugs Limited (DIN: 01895602), on 29th May 2026 at 18:32:41 IST. The communication was addressed to BSE Limited at Phiroze Jeejeebhoy Towers, 21st Floor, Dalal Street, Mumbai - 400001.
Financial Impact
No financial impact disclosed as the filing represents a regulatory compliance exemption certification rather than a financial transaction or operational update.